Table 4.
The clinical trials exploring the efficacy of α-PD-1/PD-L1 combined with angiogenesis inhibitor
| Clinical trial | Phase | α-PD-1/PD-L1 | Angiogenesis inhibitor | Cancer type | Primary outcome measures |
|---|---|---|---|---|---|
| NCT02853331 | 3 | Pembrolizumab | Axitinib | RCC | PFS, OS |
| NCT02501096 | 1b/2 | Pembrolizumab | Lenvatinib | Solid tumors | MTD, ORR, DLT |
| NCT03517449 | 3 | Pembrolizumab | Lenvatinib | Endometrial cancer | PFS, OS |
| NCT02366143 | 3 | Atezolizumab | Bevacizumab plus chemotherapy | Non-Squamous NSCLC | PFS, OS |
| NCT03434379 | 3 | Atezolizumab | Bevacizumab | HCC | PFS, OS |
| NCT03141177 | 3 | Nivolumab | Cabozantinib | RCC | PFS |
| NCT02684006 | 3 | Avelumab | Axitinib | RCC | PFS, OS |
| NCT03628521 | 1b | Sintilimab | Anlotinib | NSCLC | Safety, ORR |
| NCT03794440 | 2/3 | Sintilimab | IBI305 | HCC | PFS, OS |
| NCT02942329 | 1/2 | Camrelizumab | Apatinib | Gastric cancer, HCC | OS rate |
| NCT03417895 | 2 | Camrelizumab | Apatinib | SCLC | Safety, ORR |
| NCT03816553 | 2 | Camrelizumab | Apatinib | Cervical cancer | ORR |
| NCT03394287 | 2 | Camrelizumab | Apatinib | TNBC | ORR |
| NCT03359018 | 2 | Camrelizumab | Apatinib | Osteosarcoma | PFS, CBR |
| NCT03086174 | 1 | Toripalimab | Axitinib | Kidney cancer, melanoma | Safety |
Abbreviations: NSCLC non-small cell lung cancer, MDT maximum tolerated dose, DLT dose limiting toxicity, PFS progression-free survival, OS overall survival, SCLC small cell lung cancer, NSCLC non-small cell lung cancer, RCC renal cell carcinoma, TNBC triple-negative breast cancer, HCC hepatocellular carcinoma, CBR clinical benefit rate